Germany · Delayed Price · Currency is EUR MedinCell Company Description
MedinCell S.A., a clinical-stage and commercial biopharmaceutical licensing company, develops long acting injectables in various therapeutic areas in France.
The company develops solutions based on BEPO, a long-acting injectable technology. It offers UZEDY (mdc-IRM) for the treatment of schizophrenia in adults and bipolar I disorder.
It is also developing mdc-TJK, a subcutaneous injection that is in the NDA preparation stage for the treatment of schizophrenia in adults; and mdc-CWM, a sustained-release formulation of celecoxib in Phase III trials for use in the treatment of reduction of postoperative pain and inflammation in total knee arthroplasty surgery.
In addition, its product candidates in preclinical trials include mdc-WWM for contraception; and mdc-STM for malaria.
It has strategic collaborations with AbbVie to develop, manufacture, and commercialize six long-acting injectable therapeutic products; and IM4TB to develop a long-acting injectable version of Macozinone for the treatment of tuberculosis.
MedinCell S.A. was incorporated in 2003 and is based in Jacou, France.
| Country | France |
| Founded | 2003 |
| Industry | Pharmaceutical Preparations |
| Employees | 131 |
| CEO | Christophe Douat |
Contact Details
Address: 3 Rue des Frères Lumière Jacou, 34830 France | |
| Phone | 33 4 67 02 13 67 |
| Website | medincell.com |
Stock Details
| Ticker Symbol | MEB |
| Exchange | Frankfurt Stock Exchange |
| Fiscal Year | April - March |
| Reporting Currency | EUR |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Christophe Douat | Chief Executive Officer |
| Stephane Postic | Chief Financial Officer |
| Philippe Moyen | Chief Operating Officer |